Crinetics appoints Tobin Schilke as CFO effective Feb 28, 2025

Crinetics Pharmaceuticals, Inc.

Tobin Schilke appointed CFO effective February 28, 2025, succeeding Marc Wilson.
Schilke was previously CFO at Revance Therapeutics (2018-2025) and Achaogen.
Base salary $540,000; target bonus 40% of salary; inducement grant of 52,000 RSUs and option for 80,000 shares.
Marc Wilson's departure was previously announced in August 2024 for personal reasons.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tobin "Toby" Schilke

Chief Financial Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2025-02-28
Filed: February 24, 2025, 6:59 PM ET

On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tobin "Toby" Schilke was appointed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-025248

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.